학술논문
IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study
Document Type
article
Author
Sergio Gil-Manso; Roberto Alonso; Pilar Catalán; Ignacio Sánchez-Arcilla; Marco Marzola; Rafael Correa-Rocha; Marjorie Pion; Patricia Muñoz; Gregorio Marañón Microbiology-ID COVID-19 Study Group; Luis Alcalá; Teresa Aldámiz; Beatriz Álvarez; Ana Álvarez-Uría; Alexi Arias; Elena Bermúdez; Emilio Bouza; Sergio Buenesta do-Serrano; Almudena Burillo; Raquel Carrillo; Emilia Cercenado; Alejandro Cobos; Cristina Díez; Pilar Escribano; Agustín Estévez; Chiara Fanciulli; Alicia Galar; Mª Dolores García; Darío García de Viedma; Paloma Gijón; Adolfo González; Helmuth Guillén; Jesús Guinea, Marta Herranz; Álvaro Irigoyen; Laura Vanessa Haces; Martha Kestler; Juan Carlos López; Carmen Narcisa Losada; Marina Machado; Mercedes Marín; Pablo Martín-Rabadán; Andrea Molero-Salinas; Pedro Montilla, Patricia Muñoz; María Olmedo; Belén Padilla; Rosalía Palomino-Cabrera; María Palomo; María Jesús Pérez-Granda; Daniel Peñas-Utrilla; Laura Pérez-Lago; Leire Pérez; Elena Reigadas; Cristina Rincón; Belén Rodríguez; Sara Rodríguez; Cristina Rodríguez-Grande; Adriana Rojas; María Jesús Ruiz-Serrano; Carlos Sánchez; Mar Sánchez; Amadeo Sanz-Pérez; Julia Serrano; Francisco Tejerina; Maricela Valerio; Mª Cristina Veintimilla; Lara Vesperinas; Teresa Vicente; Sofíade la Villa
Source
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Subject
Language
English
ISSN
2235-2988
Abstract
IntroductionSince the COVID-19 outbreak, specific mRNA-based anti-SARS-CoV-2 vaccines have been developed and distributed worldwide. Because this is the first time that mRNA vaccines have been used, there are several questions regarding their capacity to confer immunity and the durability of the specific anti-SARS-CoV-2 response. Therefore, the objective of this study was to recruit a large cohort of healthcare workers from the Gregorio Marañón Hospital vaccinated with the mRNA-1273 or BNT126b2 vaccines and to follow-up on IgG anti-RBD levels at 8 months post-vaccination.MethodsWe recruited 4,970 volunteers and measured IgG anti-RBD antibodies on days 30 and 240 post-vaccination.ResultsWe observed that both vaccines induced high levels of antibodies on day 30, while a drastic wane was observed on day 240, where mRNA-1273 vaccinated induced higher levels than BNT162b2. Stratifying by vaccine type, age, gender, and comorbidities, we identified that older mRNA-1273-vaccinated volunteers had higher antibody levels than the younger volunteers, contrary to what was observed in the BNT162b2-vaccinated volunteers.DiscussionIn conclusion, we observed that mRNA-1273 has a higher capacity to induce a humoral response than BNT162b2 and that age is a factor in the specific response.